Amgen Inc. Files 8-K on Financials
Ticker: AMGN · Form: 8-K · Filed: 2024-10-30T00:00:00.000Z
Sentiment: neutral
Topics: financials, sec-filing, debt
Related Tickers: AMGN
TL;DR
Amgen dropped an 8-K detailing financials and exhibits.
AI Summary
Amgen Inc. filed an 8-K on October 30, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The filing details information related to its common stock and senior notes due in 2026.
Why It Matters
This filing provides crucial updates on Amgen's financial performance and condition, which can influence investor decisions and market perception.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Amgen Inc. (company) — Registrant
- October 30, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-37702 (filing_id) — Commission File Number
- 95-3540776 (tax_id) — IRS Employer Identification No.
- One Amgen Center Drive, Thousand Oaks, California 91320-1799 (address) — Principal executive offices
- A2.00 Senior Notes Due 2026 (debt_instrument) — Financial Instrument Mentioned
FAQ
What specific financial results are detailed in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but specific numerical results are not provided in the header information.
When was this 8-K report filed?
The report was filed on October 30, 2024.
What is Amgen Inc.'s state of incorporation?
Amgen Inc. is incorporated in Delaware.
What is the Commission File Number for Amgen Inc.?
The Commission File Number for Amgen Inc. is 001-37702.
Are there any specific financial instruments mentioned in the filing header?
Yes, the filing header mentions 'A2.00 Senior Notes Due 2026'.
From the Filing
0000318154-24-000042.txt : 20241030 0000318154-24-000042.hdr.sgml : 20241030 20241030160604 ACCESSION NUMBER: 0000318154-24-000042 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241030 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 241410289 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 8-K 1 amgn-20241030.htm 8-K amgn-20241030 0000318154 false 0000318154 2024-10-30 2024-10-30 0000318154 exch:XNGS us-gaap:CommonStockMember 2024-10-30 2024-10-30 0000318154 exch:XNGS amgn:A2.00SeniorNotesDue2026Member 2024-10-30 2024-10-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024  - Amgen Inc. (Exact name of registrant as specified in its charter)    Delaware   001-37702   95-3540776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) One Amgen Center Drive   Thousand Oaks California 91320-1799 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code ( 805 ) 447-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value AMGN The Nasdaq Stock Market LLC 2.000% Senior Notes due 2026 AMGN26 The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. Third Quarter 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On October 30, 2024 , the Company issued a press release announcing its unaudited results of operations for the three and nine months ended September 30, 2024, and its unaudited financial position as of September 30, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Reg